Evaluation for the effectiveness of Sacubitril-valsartan for acute type B aortic dissection.

Evaluation for the effectiveness of Sacubitril-valsartan for acute type B aortic dissection. - Evaluation for the effectiveness of Sacubitril-valsartan for acute type B aortic dissection.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000046000

Enrollment

200

Registered

2021-12-01

Start date

2021-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute type B aortic dissection

Interventions

Sacubitril-valsartan will be administered for a week after the onset additionally to the basic anti-hypertensive medicine. Control group. Patients will be treated with anti-hypertensive medicine witho

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with acute type B aortic dissection who are treated with conservative antihypertensive treatment

Exclusion criteria

Exclusion criteria: Complicated cases necessitate emergent or urgent surgery, patients with dialysis, patients who cannot take medicine orally, patients who cannot accept the informed consent

Design outcomes

Primary

Measure	Time frame
We evaluate the change of renal function during the conservative treatment of aortic dissection for a week after the onset. Blood tests and urine samples will be evaluated.	—

Countries

Japan

Contacts

Public ContactKotone Tsujimoto

Kawasaki Medical School General Medical Center Department of General Surgery

kosaka.r@med.kawasaki-m.ac.jp0862252111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026